ULBP antibodies

Details ULBP antibodies ULBP antibodies

2007-03-20

2007-03-20

Campell, Bruce R. (Department: 1648)

Chemistry: natural resins or derivatives; peptides or proteins;

Proteins, i.e., more than 100 amino acid residues

Blood proteins or globulins, e.g., proteoglycans, platelet...

C530S387300, C530S388100, C435S326000, C435S070100, C435S070200, C435S070210

Reexamination Certificate

active

10875869

ABSTRACT:
The invention is directed to purified and isolated novel ULBP polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above. ULBP polypeptide can be found on the surface of human B cell lymphomas. Mammalian forms of ULBP polypeptide in isolated or purified forms are provided. In addition, isolated nucleic acids encoding ULBP polypeptides and expression vectors comprising a cDNA encoding ULBP polypeptides are provided. The ULBP polypeptides can be isolated or synthesized and used to prepare antibodies, and in particular monoclonal antibodies, against the polypeptides. The antibodies, in turn, are useful for detecting the presence of ULBP polypeptides in human cell samples, which can be correlated with the existence of a malignant condition in a patient. ULBP polypeptides stimulate IFN-γ production, NK cell proliferation, and CTL activity.

REFERENCES:
patent: 4959314 (1990-09-01), Mark et al.
patent: 5474771 (1995-12-01), Lederman et al.
patent: RE38824 (2005-10-01), Salahuddin et al.
patent: 6953842 (2005-10-01), Vandlen et al.
patent: 2002/0197674 (2002-12-01), Ashkenazi et al.
Bowie et al., Science, vol. 247 No. 4948, pp. 1306-1310 (Mar. 1990).
Zurawski et al., The EMBO Journal, vol. 12 No. 13, pp. 5113-5119 (1993).
Ahn and Kunkel, “The structural and functional diversity of dystrophin,”Nat Genet 3:283-291, 1993.
Bauer et al., “Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA,”Science 285:727-729, 1999.
Bork P., “Powers and pitfalls in sequence analysis: the 70% hurdle,”Genome Research 10:398-400, 2000.
Burgess et al., “Possible dissociation of the heparin-binding and mitogenic activities of heparin-binding (Acidic Fibroblast) growth factor-1 from its receptor-binding activities by site-directed mutagenesis of a single lysine residue,”Journal of Cell Biology 111:2129-2138, 1990.
Cawthon, RM et al., “cDNA sequence and genomic structure ofEV12B, a gene lying within an intron of the neurofibromatosis type 1 gene,”Genomics 9:446-460, 1991.
Cerwenka et al., “Retinoic acid earlyinducible genes define a ligand family for the activating NKG2D receptor in mice,”Immunity 12:721-727, 2000.
Colucci et al., “Functional dichotomy in natural killer cell signaling: Vav1-dependent and -independent mechanisms,”J. Exp. Med. 193(12):1413-1424, 2001.
Cruse et al., Illustrated dictionary of immunology, CRC Press Inc. Boca Raton, FL (1995) pp. 171-172.
Diefenbach, A, et al., “Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity,”Nature 413:165-171, 2001.
Dorfman, D. et al., “In vivo expression of B7-1 and B7-2 by follicular lymphoma cells can prevent induction of T-cell anergy but is insufficient to induce significant T-cell proliferation,”Blood 90(11):4297-4306, 1997.
Gattei, V, et al., “CD30 ligand is frequently expressed in human hematopoietic malignancies of myeloid and lymphoid origin,”Blood 89(6):2048-2059, 1997.
GenBank Accession No. A1091180, 1997.
GenBank EST Database Accession No. A1830832, (gi:5451425) wj52c06.x1 NCI—CGAP—Lu19Homo sapienscDNA clone (see USPTO Search Report US-09-597-2.rst, result 1), 1999.
GenBank Accession No. U56940 (gi:1708675), “Human MHC class I chain-related gene A (MICA 001 allele), partial cds,” 1997.
GenBank Accession No. U65416 (gi:1815636), “Human MHC class I molecule (MICB) gene, complete cds,” 1997.
GenBank Accession No. R25716, 1995.
Girardi, M, et al., “Regulation of cutaneous malignancy by γδ T cells,”Science 294:605-609, 2001.
Gura, T, “Systems for identifying drugs are often faulty,”Science 278:1041-1042, 1997.
Harris, PC et al., “Polycystic kidney disease 1: identification and analysis of the primary defect,”J Am Soc Nephrol 6:1125-1133, 1995.
Janeway et al., Immunobiology, Current Biology Ltd., London (1994) pp. 9:20-9:24.
Lazar et al., “Transforming growth factor alpha: mutation of aspartic acid 47 and leucine 48 results in different biological activities,”Molecular and Cellular Biology 8:1247-1252, 1998.
Luo et al., “Rat hepatic natural killer cells (pit cells) express mRNA and protein similar toin VitroInterleukin-2 activated spleen natural killer cells,”Cell. Immunol. 210:41-48, 2001.
Myers, D and Uckun, F, “An anti-CD72 immunotoxin against therapy-refractory B-lineage acute lymphoblastic leukemia,”Leukemia and Lymphoma 18:119-122, Harwood Academic Publishers GmbH, Printed in Singapore, 1995.
Scott et al., “The pendered syndrome gene encodes a chloride-iodide transport protein,”Nature Genetics 21:440-443, 1999.
Steinle, A, et al., Interactions of human NKG2D with its ligands MICA, MICB, and homologs of the mouse RAE-1 protein family,Immunogenetics 53:279-287, 2001.
Sun, T, et al., “Histiocyte-rich B-cell lymphoma,”Human Pathology 28(11):1321-1324, 1997.
Whiteside, T and Herberman, R, “The role of natural killer cells in immune surveillance of cancer,”Current Opinion in Immunology 7:704-710, 1995.
Yamabe et al., “Induction of the 2B9 antigen/dipeptiyl peptidase IV/CD26 on human natural killer cells by IL-2, IL-12 and IL-15,”Immunology 91:151-158, 1997.

Affiliated with

Also associated with

Rating

ULBP antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with ULBP antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and ULBP antibodies will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3805313